Healthcare & Medical Devices Global On demand · 24-48h

Global Endocrinology and Metabolism Market Strategic Research Report

Global Endocrinology and Metabolism Market Strategic Researc…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Endocrinology and Metabolism Market
$103.26B2025
11.6%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Diabetes Drugs, HGH, Thyroid Hormone Disorders, Others

By Application: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Abbott Laboratories, Acerus Pharmaceuticals Corp., Ascendis Pharma AS, Bayer AG, Beta Cell NV, Biocon Ltd., Eli Lilly and Co., Endo International Plc, Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Hanmi Pharm Co. Ltd., Ipsen Pharma

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 120 pages
Market size 2025
$103.26B
Billion USD
Forecast CAGR
11.6%
2025-2032
Forecast 2032
$222.6B
Projected
Régions
5
Asia Pacific · Latin America · MEA · Europe · North America

Vue d'ensemble

Scope of the Report

The global Endocrinology and Metabolism market size is predicted to grow from US$ 103,260 million in 2025 to US$ 219,670 million in 2032; it is expected to grow at a CAGR of 11.6% from 2026 to 2032.

Endocrinology is the internal medicine subspecialty dedicated to the diagnosis and care of diseases and conditions related to the endocrine glands, hormones, and metabolism, the body’s physical and chemical processes to use energy or convert it for use. These diseases and conditions include type 1 and type 2 diabetes; obesity; conditions of the pituitary, thyroid, parathyroid, and adrenal glands; and metabolic disorders.

The rising frequency of endocrine problems, including diabetes, thyroid disorders, and hormonal imbalances, is another major factor driving the endocrinology and metabolism market. Sedentary lifestyles, bad eating habits, rising obesity rates, and an aging population all contribute to the growing global burden of endocrine illnesses. As the frequency and prevalence of these problems rise, so does the demand for diagnostic tests, medicines, and treatment procedures that address endocrine and metabolic abnormalities. This spike in demand opens up attractive prospects for market players to offer innovative products and services to meet the growing healthcare needs of people with endocrine diseases.

This report presents a comprehensive overview of the global Endocrinology and Metabolism market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Diabetes Drugs
  • HGH
  • Thyroid Hormone Disorders
  • Others

Segment by Application

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Endocrinology and Metabolism market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Hospital Pharmacies, Retail Pharmacies, Online Pharmacies evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Endocrinology and Metabolism Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 11.6%
Regional growth momentum
Market share by segment
Key metrics
Base value
$103.26B
2025
Forecast
$222.6B
2032
CAGR
11.6%
2025–2032
Régions
5
global
Key companies
Abbott LaboratoriesAcerus Pharmaceuticals Corp.Ascendis Pharma ASBayer AGBeta Cell NVBiocon Ltd.Eli Lilly and Co.Endo International Plc
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Diabetes DrugsHGHThyroid Hormone DisordersOthers
By Application
Hospital PharmaciesRetail PharmaciesOnline Pharmacies

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Diabetes Drugs
  • 3.1.3 HGH
  • 3.1.4 Thyroid Hormone Disorders
  • 3.1.5 Others
  • 3.1.6 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Hospital Pharmacies
  • 4.1.3 Retail Pharmacies
  • 4.1.4 Online Pharmacies
  • 4.1.5 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Abbott Laboratories
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Acerus Pharmaceuticals Corp.
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Ascendis Pharma AS
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Bayer AG
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Beta Cell NV
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Biocon Ltd.
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Eli Lilly and Co.
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Endo International Plc
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Hoffmann La Roche Ltd.
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 GlaxoSmithKline Plc
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Hanmi Pharm Co. Ltd.
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Ipsen Pharma
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

How big is the global Endocrinology and Metabolism market?
The global Endocrinology and Metabolism market is estimated at US$ 103.26 billion in 2025 (base year) and is projected to reach US$ 219.67 billion by 2032.
How fast is the Endocrinology and Metabolism market expected to grow?
The market is expected to grow at a CAGR of 11.6% from 2026 to 2032, expanding from US$ 103.26 billion in 2025 to US$ 219.67 billion in 2032, roughly 2.1 times its base-year value.
What does the Endocrinology and Metabolism market cover?
Endocrinology is the internal medicine subspecialty dedicated to the diagnosis and care of diseases and conditions related to the endocrine glands, hormones, and metabolism, the body’s physical and chemical processes to use energy or convert it for use. These diseases and conditions include type 1 and type 2 diabetes; obesity; conditions of the pituitary, thyroid, parathyroid, and adrenal glands; and metabolic disorders.
What are the main segments of the Endocrinology and Metabolism market by type?
By type, the market is segmented into Diabetes Drugs, HGH, Thyroid Hormone Disorders and Others.
Which applications drive demand in the Endocrinology and Metabolism market?
Key applications covered include Hospital Pharmacies, Retail Pharmacies and Online Pharmacies.
Who are the key players in the Endocrinology and Metabolism market?
Key players profiled include Abbott Laboratories, Acerus Pharmaceuticals Corp., Ascendis Pharma AS, Bayer AG, Beta Cell NV, Biocon Ltd., Eli Lilly and Co. and Endo International Plc, among 12 companies covered in total.
Which regions and countries are covered for Endocrinology and Metabolism?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What is driving growth in the Endocrinology and Metabolism market?
The rising frequency of endocrine problems, including diabetes, thyroid disorders, and hormonal imbalances, is another major factor driving the endocrinology and metabolism market.
Who should buy the Endocrinology and Metabolism market report?
The report is intended for manufacturers and solution providers, distributors and end users in Hospital Pharmacies, Retail Pharmacies and Online Pharmacies, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Endocrinology and Metabolism market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from 3 500,00 $US
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.